Diabetes Drug Development Labelling 
STAT
NOVEMBER 10, 2023
regulators in Europe on Friday recommended that the approval of Eli Lilly’s diabetes drug Mounjaro be widened to include obesity. Doctors have been prescribing the diabetes drugs off-label for obesity, but having specific authorization could streamline the process of getting the medicines.
Express Pharma
DECEMBER 2, 2024
The company’s Phase III product Rybelsus, already FDA approved for cardiovascular risk factors and type 2 diabetes, is being positioned for a label expansion to include obesity. Novo Nordisk is leading the pack with four separate products, two apiece in Phase III and Phase II.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Express Pharma
JULY 1, 2024
Momna Ali, Healthcare Analyst at GlobalData, states, “Amylyx’s acquisition of avexitide marks its entry into the drug development field for metabolic diseases, a departure from its prior focus on neurodegenerative diseases. This shift in strategy comes after Relyvrio’s disappointing efficacy results from the drug’s confirmatory trial.
Pharmaceutical Technology
NOVEMBER 30, 2022
In what’s being called a “medical bypass”, new anti-obesity drugs are almost matching efficacy rates in weight loss that have previously only been seen with weight loss surgeries. The drug was approved to treat type 2 diabetes mellitus in May. weight reduction in obese individuals, as per its label. million in Q3.
Pharmaceutical Technology
NOVEMBER 30, 2022
In what’s being called a “medical bypass”, new anti-obesity drugs are almost matching efficacy rates in weight loss that have previously only been seen with weight loss surgeries. The drug was approved to treat type 2 diabetes mellitus in May. weight reduction in obese individuals, as per its label. million in Q3.
pharmaphorum
AUGUST 5, 2020
Importantly, multimorbidity occurs as clusters of diseases, and whilst there are different views on what the clusters are and how many exist, Lord says that most would agree there are three main clusters: Cardiovascular/metabolic – including heart disease, hypertension and Type 2 diabetes. The hallmarks of aging. Cell 2013; 153(6):1194–1217.
The Nontraditional Pharmacist
SEPTEMBER 9, 2019
Or if you are interested in diabetes in the Ambulatory Care space if you were providing direct patient care to patients with diabetes you know that would be very beneficial getting that clinical experience. That’s sort of the traditional MSL role, so that’s really what my role is.
Expert insights. Personalized for you.
251 
Let's personalize your content